Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 3

1(14.3%)

7Total

Phase 1(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07112443Phase 3Recruiting

A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

Role: lead

NCT05987033Phase 1Completed

Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.

Role: lead

NCT05961956Phase 1Active Not Recruiting

Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis

Role: lead

NCT06532253Phase 1Recruiting

Long-term Safety Trial with NVDX3

Role: lead

NCT06335394Phase 1Active Not Recruiting

Prospective Study in Adults Evaluating Safety & Efficacy of NVD003 for Bone Reconstruction to Treat Lower Limb Nonunion

Role: lead

NCT05693558Phase 1Unknown

NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia

Role: lead

NCT03100032Phase 1Completed

Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis

Role: lead

All 7 trials loaded